SVA Sinovac Biotech
- 6.470
- 0.0000.00%
Sinovac Biotech News
Sinovac Biotech Embraces Post-Pandemic Challenges
Sinovac Biotech 2H Sales $307.9 >SVA
Sinovac Biotech 2H Sales $307.9 >SVA
Seasonal Influenza Global Clinical Trials Review 2024 Featuring GSK, Novartis, Johnson & Johnson, Novavax, CSL, Sinovac Biotech, Moderna, and Sanofi, Among Others
Sinovac: Given Ongoing Litigation Concerning Exchange of Shares & Rights Agreement, Unclear If or When Halt Will Lift >SVA
Sinovac: Given Ongoing Litigation Concerning Exchange of Shares & Rights Agreement, Unclear If or When Halt Will Lift >SVA
Sinovac Is a China-based Biopharma Co With Vaccine Portfolio Including Covid, Hep A >SVA
Sinovac Is a China-based Biopharma Co With Vaccine Portfolio Including Covid, Hep A >SVA
Sinovac: These Inlcude That Trading of Company's Shares on Nasdaq Has Been Halted Since February 2019 >SVA
Sinovac: These Inlcude That Trading of Company's Shares on Nasdaq Has Been Halted Since February 2019 >SVA
Sinovac: Board Also Considered Other Material Risks >SVA
Sinovac: Board Also Considered Other Material Risks >SVA
Sinovac: Also Has $9.4B in Short-Term Investments, Posted 1H $14.0M in Net Income >SVA
Sinovac: Also Has $9.4B in Short-Term Investments, Posted 1H $14.0M in Net Income >SVA
Sinovac: This Suggests Lack of Credibility in Alternative Liquidity's Valuation >SVA
Sinovac: This Suggests Lack of Credibility in Alternative Liquidity's Valuation >SVA
Sinovac: Cash Position of $1.6B as of End June Represents $14.40/Share >SVA
Sinovac: Cash Position of $1.6B as of End June Represents $14.40/Share >SVA
Sinovac: Offer's Implied Valuation Is Less Than Company's Assets Value >SVA
Sinovac: Offer's Implied Valuation Is Less Than Company's Assets Value >SVA
Sinovac Board Recommends That Shareholders Reject Tender Offer >SVA
Sinovac Board Recommends That Shareholders Reject Tender Offer >SVA
Alternative Liquidity Had Made Cash Offer for Up to 10M Common Sinovac Shares for $0.03 Each >SVA
Alternative Liquidity Had Made Cash Offer for Up to 10M Common Sinovac Shares for $0.03 Each >SVA
Sinovac Biotech Board Unanimously Rejects an Unsolicited Partial Tender Offer From Alternative Liquidity Index To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanim
Global Hand, Foot, and Mouth Disease Analysis Report, 2017-2022 & 2023-2030 Featuring Emergex Vaccines, Bejing Vigoo Biological, Shanghai Zerun Biotechnology, Sentinext Therapeutics, & Sinovac Biotech
DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The "Global Hand, Foot, and Mouth Disease Market, By Virus Type; By Drug Type; By Route of Administration; By Distribution Channel -Estimation & Forecast, 2017-2030"
Sinovac Biotech Confirms $0.03/shr Purchase Offer For Its 10 Mln Shares
Sinovac Is a China-based Biopharma Co With Products Including Vaccines Against Covid, Hepatitis >SVA
Sinovac Is a China-based Biopharma Co With Products Including Vaccines Against Covid, Hepatitis >SVA
Sinovac Board to Evaluate Offer Terms, Will Tell Shareholders Position Within 10 Days >SVA
Sinovac Board to Evaluate Offer Terms, Will Tell Shareholders Position Within 10 Days >SVA
Sinovac: Amount Represents About 10% of Company's Outstanding Shrs >SVA
Sinovac: Amount Represents About 10% of Company's Outstanding Shrs >SVA
Sinovac: Alternative Liquidity Index Has Made Offer to Buy Up 10M Shrs for $0.03 Each >SVA
Sinovac: Alternative Liquidity Index Has Made Offer to Buy Up 10M Shrs for $0.03 Each >SVA
Analysis
Price Target
No Data
